Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Investors Fret Over Roundup Liability

share with twitter share with LinkedIn share with facebook
share via e-mail
05/15/2019 | 02:48am EDT

By Ruth Bender

BERLIN -- Bayer AG shares resumed their monthslong fall on Tuesday after the company was hit by a more-than $2 billion jury award over its Roundup herbicide, marking a sharp escalation in the chemical and drug giant's legal woes.

The shares were down 2.3% in Europe -- one of the worst performers in the Frankfurt stock exchange's blue-chip DAX index, which was trading up on the day -- after hitting a seven-year low. The fall followed Bayer's third Roundup court defeat in 10 months. A California jury on Monday awarded $2.055 billion to a couple who blamed the weedkiller for causing their cancer, a significantly higher amount than the two-digit million figures Bayer is facing in previous cases.

The verdict overshadowed the first positive news from Bayer in weeks. On Monday, the company said it had reached an agreement to sell its Coppertone sunscreens for $550 million, the first of a series of emergency restructuring measures it planned late last year in an effort to convince increasingly skeptical investors that it has its drugs-to-crops business under control.

Without a court win so far, Bayer has been stuck in a downward spiral, with each new verdict against it pushing its stock lower as shareholders struggled to compute the total scale of the company's potential liabilities surrounding Roundup.

"Sentiment is stuck in the mud," said Citi analyst Peter Verdult, who is now pinning his hopes on the next Roundup trial in St. Louis, which will be the first to take place outside the San Francisco Bay Area, often seen as an unfavorable setting for corporate defendants.

"A positive development of the group's business probably won't have an effect on valuation in the short term," analysts from DZ Bank wrote.

Bayer is appealing all verdicts. The company argues Roundup and its active ingredient glyphosate are safe to use. It hopes to win on appeal, where judges will look over the cases.

After the first verdict, Bayer obtained a substantial reduction in the amount of the award and analysts were optimistic Tuesday that this week's $2 billion award would be reduced too.

Gunther Zechmann from Bernstein research said he expected Monday's award, which included $2 billion in punitive damages, to conclude at $110 million.

Still, the amount granted by the jury this week could make the 13,400 total plaintiffs that Bayer still faces more hesitant to reach a settlement "given the prize available through winning their case," Mr. Zechmann said.

Some investors would like to see Bayer settle sooner rather than later to get clarity over the future of the company.

Write to Ruth Bender at Ruth.Bender@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -1.11% 65.24 Delayed Quote.7.73%
DAX -0.17% 12633.6 Delayed Quote.19.65%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
10/17BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
10/16ATOS : Signs Contract With Bayer for Digital Workplace Services
10/16BAYER : Animal Health and VLPbio sign global collaboration agreement
10/15BAYER : U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill..
10/15J&J's Courtroom Losses Pile Up -- WSJ
10/14Early Blizzard Wallops Vulnerable Crops
10/14J&J'S JANSSEN : FDA OK's Xarelto in Acutely Ill Medical Patients
10/14BAYER : U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill..
10/14Johnson & Johnson's Legal Challenges Mount
More news
Financials (EUR)
Sales 2019 46 036 M
EBIT 2019 7 933 M
Net income 2019 3 095 M
Debt 2019 37 372 M
Yield 2019 4,36%
P/E ratio 2019 21,1x
P/E ratio 2020 13,4x
EV / Sales2019 2,13x
EV / Sales2020 2,01x
Capitalization 60 840 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 79,26  €
Last Close Price 65,24  €
Spread / Highest target 88,5%
Spread / Average Target 21,5%
Spread / Lowest Target -40,6%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG7.73%67 773
JOHNSON & JOHNSON5.52%337 021
ROCHE HOLDING AG18.49%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVARTIS15.95%198 751